Leerink Partnrs Has Bearish Estimate for IRWD Q4 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Leerink Partnrs cut their Q4 2024 EPS estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings of $0.08 per share for the quarter, down from their prior estimate of $0.09. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2025 earnings at $0.07 EPS, FY2025 earnings at $0.06 EPS and FY2026 earnings at $0.36 EPS.

IRWD has been the subject of a number of other reports. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. Finally, JMP Securities cut their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $10.67.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock opened at $2.34 on Friday. Ironwood Pharmaceuticals has a fifty-two week low of $2.23 and a fifty-two week high of $15.70. The company has a market cap of $374.47 million, a PE ratio of -78.00 and a beta of 0.34. The stock’s fifty day moving average price is $3.88 and its two-hundred day moving average price is $4.48.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The firm had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company’s quarterly revenue was down 19.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.12 earnings per share.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its holdings in Ironwood Pharmaceuticals by 48.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 213,619 shares of the biotechnology company’s stock worth $1,393,000 after acquiring an additional 69,848 shares during the period. Hsbc Holdings PLC increased its holdings in shares of Ironwood Pharmaceuticals by 60.2% in the second quarter. Hsbc Holdings PLC now owns 25,923 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 9,740 shares during the period. AQR Capital Management LLC raised its position in shares of Ironwood Pharmaceuticals by 45.7% in the second quarter. AQR Capital Management LLC now owns 684,578 shares of the biotechnology company’s stock worth $4,463,000 after buying an additional 214,836 shares in the last quarter. Algert Global LLC bought a new stake in Ironwood Pharmaceuticals during the second quarter valued at $93,000. Finally, Handelsbanken Fonder AB boosted its stake in Ironwood Pharmaceuticals by 24.2% during the third quarter. Handelsbanken Fonder AB now owns 59,455 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 11,600 shares during the period.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 12.90% of the stock is currently owned by company insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.